A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

Inclusion criteria

• Clinically definite MS with disease duration (from onset) of at least 6 months.
• Subjects must have had at least 1 documented relapse within the last year prior to study entry.
• Subjects must have at least 1 and not more than 15 gadolinium (Gd)-enhancing lesions on the screening MRI scan.
• Subjects must be relapse-free and not have taken corticosteroids (IV, IM and/or PO) within the 30 days prior to the screening visit.
• Subjects must not have taken corticosteroids (IV, IM and/or PO) between the screening and baseline visits.
• Subjects may be male or female. Women of child- bearing potential must practice a medically acceptable method of birth control. Acceptable methods include oral contraceptive, contraceptive patch, or double-barrier method (condom or IUD with spermicide).
• Subjects must be between the ages of 18 and 50 years inclusive.
• Subjects must be ambulatory, with a Kurtzke EDSS score of between 0 and 5 inclusive.
• Subjects must be willing and able to give written informed consent prior to entering the study.

Exclusion criteria

• Previous use of glatiramer acetate (oral or injectable).
• Previous use of cladribine.
• Previous use of immunosuppressive agents in the last 6 months.
• Use of experimental or investigational drugs, including I.V. immunoglobulin, and/or participation in an investigational drug study within 6 months prior to study entry.
• Use of interferon agents within 60 days prior to the screening visit.
• Chronic corticosteroid (IV, IM and/or PO) treatment (more than 30 consecutive days) in the 6 months prior to study entry.
• Previous total body irradiation or total lymphoid irradiation (TLI).
• Pregnancy or breast feeding.
• Patients who experience a relapse between the screening (month -1) and baseline (month 0) visits.
• Any condition which the investigator feels may interfere with participation in the study, including alcohol and/or drug abuse.
• A known history of sensitivity to mannitol.
• A known sensitivity to gadolinium.
• Inability to successfully undergo MRI scanning.